Shares of Legend Biotech rose more than 40% Tuesday—on pace for the stock's biggest percentage increase on record—after the company said its experimental cancer treatment shrank tumors in all six ...

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin ...

Lilly's Jake Van Naarden is meeting myeloma experts at ASCO to figure out the best possible path for phase 3 trials of Kelonia's in vivo CAR-T prospect. (Darren Incorvaia) Kelonia Therapeutics has ...

Joshua started at GameRant in 2017 where he fell in love with a company that supports creativity, treats video games with the respect they deserve, and is complete with people whose passions match his ...